Loading...
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
0874.HK•HKSE
HealthcareDrug Manufacturers - Specialty & Generic
HK$17.92
HK$0.20(1.13%)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) Financial Performance & Statements
Review Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-0.69%
↓ 0.69%
Operating Income Growth
-29.77%
↓ 29.77%
Net Income Growth
-30.09%
↓ 30.09%
Operating Cash Flow Growth
-16.11%
↓ 16.11%
Operating Margin
4.52%
↑ 4.52%
Gross Margin
16.17%
↑ 16.17%
Net Profit Margin
3.62%
↑ 3.62%
ROE
7.39%
↑ 7.39%
ROIC
7.67%
↑ 7.67%
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $15.93B | $18.02B | $18.10B | $22.95B |
| Cost of Revenue | $13.87B | $15.36B | $15.38B | $17.87B |
| Gross Profit | $2.06B | $2.66B | $2.72B | $5.08B |
| Gross Profit Ratio | $0.13 | $0.15 | $0.15 | $0.22 |
| R&D Expenses | $185.26M | $187.37M | $205.006M | $186.14M |
| SG&A Expenses | -$2.99B | $4.34B | $851.04M | $2.53B |
| Operating Expenses | $2.47B | $1.88B | $2.03B | $2.68B |
| Total Costs & Expenses | $16.34B | $17.24B | $17.40B | $20.55B |
| Interest Income | $80.53M | $45.61M | $406.33M | $128.17M |
| Interest Expense | $100.68M | $104.13M | $106.91M | $106.43M |
| Depreciation & Amortization | $0.00 | $105.79M | $129.89M | $152.81M |
| EBITDA | -$297.78M | $880.76M | $883.98M | $2.78B |
| EBITDA Ratio | -$0.02 | $0.05 | $0.05 | $0.12 |
| Operating Income | -$404.67M | $774.97M | $773.84M | $2.45B |
| Operating Income Ratio | -$0.03 | $0.04 | $0.04 | $0.11 |
| Other Income/Expenses (Net) | $6.22M | $1.66M | $3.22M | $91024.00 |
| Income Before Tax | -$398.46M | $776.63M | $777.06M | $2.45B |
| Income Before Tax Ratio | -$0.03 | $0.04 | $0.04 | $0.11 |
| Income Tax Expense | -$109.75M | $155.23M | $140.75M | $420.62M |
| Net Income | -$323.48M | $609.41M | $591.45M | $1.96B |
| Net Income Ratio | -$0.02 | $0.03 | $0.03 | $0.09 |
| EPS | -$0.20 | $0.37 | $0.36 | $1.20 |
| Diluted EPS | -$0.20 | $0.37 | $0.36 | $1.20 |
| Weighted Avg Shares Outstanding | $1.63B | $1.63B | $1.63B | $1.63B |
| Weighted Avg Shares Outstanding (Diluted) | $1.63B | $1.63B | $1.63B | $1.63B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan